Clovis Oncology (CLVS) : 6 Wall Street analysts covering Clovis Oncology (CLVS) believe that the average level the stock could reach for the short term is $24.83. The maximum price target given is $30 and the minimum target for short term is around $14, hence the standard deviation is calculated at $6.46.
Clovis Oncology (CLVS) : 3 brokerage houses believe that Clovis Oncology (CLVS) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Clovis Oncology (CLVS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 2.
Also, Major Brokerage house, SunTrust Robinson Humphrey maintains its ratings on Clovis Oncology (NASDAQ:CLVS). In the latest research report, SunTrust Robinson Humphrey raises the target price from $25 per share to $30 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 24, 2016.
Clovis Oncology (NASDAQ:CLVS): The stock opened at $25.01 on Thursday but the bulls could not build on the opening and the stock topped out at $25.30 for the day. The stock traded down to $23.14 during the day, due to lack of any buying support eventually closed down at $23.59 with a loss of -4.76% for the day. The stock had closed at $24.77 on the previous day. The total traded volume was 2,716,679 shares.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.